Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Untitled publication

Bulletin du cancer - 1 Nov 2022

Valéry Marine, Cervantes Baptiste, Smolenschi Cristina, Boige Valérie, Ducreux Michel, Cohen Romain, Hollebecque Antoine

Abstract excerpt

DNA mutations in cholangiocarcinoma: targeting IDH1 and other mutations Biliary tract cancers (BTC) are rare cancers with a poor prognosis, particularly at the metastatic stage, with a 5-year survival rate not exceeding 7%. Two lines of chemotherapy are currently recommended in France, with cisplatin-gemcitabine and 5 FU-oxaliplatin as first and second-line treatment respectively, allowing a median survival of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bile Duct Neoplasms
Share to Bile Ducts, Intrahepatic
Share to Biliary Tract Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cholangiocarcinoma

Share to Isocitrate Dehydrogenase

Share to Mutation

Source

Identifiers

PMID: 36535759
DOI: 10.1016/S0007-4551(22)00465-9

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Untitled literature recordPMID 36535759Read ↗

Targeted Therapies in Advanced Biliary Tract Cancer: An Evolving ParadigmSemantic proximity Read ↗

Genomic landscape of biliary tract cancer and corresponding targeted treatment strategiesSemantic proximity Read ↗

Molecular biology of cholangiocarcinoma and its implications for targeted therapy in patient management.Semantic proximity Read ↗

Molecular profiling of biliary tract cancer: a target rich diseaseSemantic proximity Read ↗

Evolution of Treatment in Advanced Cholangiocarcinoma: Old and New towards Precision Oncology.Semantic proximity Read ↗

Matching genomic molecular aberrations with molecular targeted agents: Are biliary tract cancers an ideal playground?Semantic proximity Read ↗

Emerging molecular target antagonists for the treatment of biliary tract cancer.Semantic proximity Read ↗

The landscape of targeted therapies for cholangiocarcinoma: current status and emerging targets.Semantic proximity Read ↗

Genomic feature and potential therapeutic target for cholangiocarcinomaSemantic proximity Read ↗

Current Status of Targeted Therapy for Biliary Tract Cancer in the Era of Precision MedicineSemantic proximity Read ↗

Biliary Tract Cancers: Molecular Heterogeneity and New Treatment OptionsSemantic proximity Read ↗

Molecular profiling of biliary cancers reveals distinct molecular alterations and potential therapeutic targetsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.